BioSeed® is a platform for innovative life science companies to present and meet with sector specific early stage investors.
The inaugural event on 14th November 2017 saw 56 CEOs and decision makers present their companies to a floor of 80 investors and pharma delegates. The attendees enjoyed in-sight full discussions facilitated by the 350 partnering one-to-one meetings which took place between companies and investors keen to learn more about investment opportunities. The event’s one day format – with presentations in the morning, a networking lunch and partnering sessions in the afternoon – offered plenty of opportunities for companies and investors to network.
BioSeed® 2017 Highlights
|Big pharma ( from Lilly, Merck, BMS, J&J, Pfizer)||15|
|Universities (from Manchester, Exeter, Edinburgh, Birmingham, UCL, RCSI, QMUL, Brunel)||8|
|1-2-1 Partnering meetings||350|
We found the BioSeed meeting to be extremely productive. Strong interest was expressed by both investors and PharmaCos with whom we met; many requested further presentational materials and background information.
Excellent selection of biotech and medtech companies seeking investment from across the UK.
Quality of many assets
Impressed by the quality of many assets presented and pitches delivered. A promising level of scientific, commercial and managerial relevance at seed stage.
A time-efficient way to meet multiple Med/Biotech companies.
Innovative opportunities for the bio-medical investment community
A full-on, pelmet rush through a bewildering range of fantastic, innovative opportunities for the bio-medical investment community! And all the more refreshing for that fast pace and high throughput. A good proportion of investable and 'ones-to-watch' start-ups and spin-outs.
Great partnering event
Great partnering event, very effective for discovering early stage opportunities.
Refreshing format for meeting a lot of new companies and a great opportunity for UK networking, all in one day.
It was a great event. Very good to see such a range of seed and series A companies in one venue. Very efficient.